Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
在 III 期试验 E1609 中，接受辅助治疗的 III-IV 期高危黑色素瘤患者报告的伊匹木单抗（3 或 10 mg/kg）与高剂量干扰素 α-2b 的耐受性比较
期刊:Quality of Life Research
影响因子:2.7
doi:10.1007/s11136-022-03226-8
McLouth, Laurie E; Zheng, Yue; Smith, Stephanie; Hodi, F Stephen; Rao, Uma N; Cohen, Gary I; Amatruda, Thomas T; Dakhil, Shaker R; Curti, Brendan D; Nakhoul, Ibrahim; Chandana, Sreenivasa R; Bane, Charles L; Marinier, David E; Lee, Sandra J; Sondak, Vernon K; Kirkwood, John M; Tarhini, Ahmad A; Wagner, Lynne I
